KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Emergent BioSolutions (EBS) Tax Provisions: 2010-2025

Historic Tax Provisions for Emergent BioSolutions (EBS) over the last 16 years, with Sep 2025 value amounting to $6.4 million.

  • Emergent BioSolutions' Tax Provisions fell 76.81% to $6.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.0 million, marking a year-over-year decrease of 23.08%. This contributed to the annual value of $47.7 million for FY2024, which is 62.80% up from last year.
  • According to the latest figures from Q3 2025, Emergent BioSolutions' Tax Provisions is $6.4 million, which was up 233.33% from -$4.8 million recorded in Q2 2025.
  • Emergent BioSolutions' 5-year Tax Provisions high stood at $78.4 million for Q4 2021, and its period low was -$26.4 million during Q2 2022.
  • Its 3-year average for Tax Provisions is $9.4 million, with a median of $6.4 million in 2025.
  • Per our database at Business Quant, Emergent BioSolutions' Tax Provisions tumbled by 1,115.38% in 2022 and then spiked by 25,700.00% in 2023.
  • Over the past 5 years, Emergent BioSolutions' Tax Provisions (Quarterly) stood at $78.4 million in 2021, then slumped by 92.86% to $5.6 million in 2022, then crashed by 189.29% to -$5.0 million in 2023, then skyrocketed by 174.00% to $3.7 million in 2024, then plummeted by 76.81% to $6.4 million in 2025.
  • Its Tax Provisions stands at $6.4 million for Q3 2025, versus -$4.8 million for Q2 2025 and $24.7 million for Q1 2025.